n-(3-pyridylmethyl)adriamycin has been researched along with Esophageal Squamous Cell Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbaszadegan, MR; Ardalan Khales, S; Forghanifard, MM; Hosseini, SE | 1 |
| Asadi, J; Jazi, MS; Khosravi, A; Kokabi, F | 1 |
2 other study(ies) available for n-(3-pyridylmethyl)adriamycin and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
EZH2 deregulates BMP, Hedgehog, and Hippo cell signaling pathways in esophageal squamous cell carcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; Signal Transduction | 2023 |
A reliable mouse model of liver and lung metastasis by injecting esophageal cancer stem cells (CSCs) through tail-vein injection.
Topics: Animals; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Liver; Lung Neoplasms; Mice; Mice, Nude; Neoplastic Stem Cells | 2023 |